Trial reportArchives of Razi Institute2025
Effect of
Trial report in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selenium (Se) is a trace mineral that plays a critical role in public health. It is a vital component of numerous enzymes and proteins called selenoproteins, thus affecting a wide range of biological activities. Hashimoto's disease is the most common cause of hypothyroidism. In addition to being a critical micronutrient for thyroid health, selenium has a direct association with liver health. The objective of this study is to examine the impact of Selenium on lipid factors, thyroid factors (anti-TPO and TSH), and liver enzymes. A double-blind, randomized clinical trial was conducted, enrolling 40 patients with Hashimoto's thyroiditis in two equal control (placebo) and intervention (Selenium) groups. Participants received 200 micrograms of Selenium over 60 days, with blood samples collected before and after the intervention. The spectrophotometric method was employed to measure total blood catalase, anti-TPO, TSH, malondialdehyde, serum lipid profile, and liver factors. The results were then subjected to statistical analysis. The study revealed a significant decrease in plasma MDA levels in response to selenium consumption. Additionally, a notable increase in hemoglobin levels was observed in the experimental group following the intervention, reaching a statistical significance of P<0.05. However, catalase enzyme, lipid profile components, and liver enzymes in the intervention group remained largely unchanged compared to the pre-intervention and control groups (P>0.05).TSH and anti-TPO levels exhibited a relative decrease in the intervention group (P>0.05). The findings of this study suggest a potential association between selenium consumption and improved serum lipid factors, liver enzymes, anti-thyroid peroxidase antibody, MDA, and HGB levels in individuals diagnosed with Hashimoto's thyroiditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.